** Shares of Akero Therapeutics AKRO.O up 1.8% premarket to $52.39 after co raises more equity than targeted
** Co late Tues said sold ~7.3 mln shares, including ~2 mln pre-funded warrants, at $48 for approx $350 mln gross proceeds
** On Mon, AKRO shares surged 97.5% to $51.71 after co said its lead drug, efruxifermin, showed it can help reverse scarring in patients with type of fatty liver disease known as metabolic dysfunction-associated steatohepatitis (MASH)
** Shares on Tues edged down 0.5% and closed at $51.47 as co marketed $300 mln offering
** Co has ~69.8 mln shares outstanding for $3.6 bln market cap, per LSEG
** JP Morgan, Morgan Stanley and Jefferies are jt bookrunners for the offering
** Separately, 89Bio ETNB.O raised $250 mln of equity to fund its MASH drug candidate
(Lance Tupper is a Reuters market analyst. The views expressed are his own)
((lance.tupper@tr.com 1-646-279-6380))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.